Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Payables: 2020-2025

Historic Payables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $1.1 million.

  • Insight Molecular Diagnostics' Payables rose 7.21% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 76.83%. This contributed to the annual value of $2.3 million for FY2024, which is 139.14% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Payables stood at $1.1 million, which was down 17.31% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Payables ranged from a high of $5.3 million in Q1 2021 and a low of $908,000 during Q1 2024.
  • In the last 3 years, Insight Molecular Diagnostics' Payables had a median value of $1.1 million in 2023 and averaged $1.4 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Payables tumbled by 70.18% in 2023, and later skyrocketed by 150.99% in 2025.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Payables stood at $2.1 million in 2021, then dropped by 12.85% to $1.8 million in 2022, then plummeted by 47.55% to $953,000 in 2023, then spiked by 139.14% to $2.3 million in 2024, then grew by 7.21% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.3 million for Q2 2025, and $2.3 million during Q1 2025.